Spironolactone for Preventing Contrast-Induced Nephropathy After Percutaneous Coronary Intervention in Patients With...

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Patients with acute myocardial infarction (AMI) and chronic kidney disease (CKD) face high risks of contrast-induced nephropathy (CIN).
• CIN can negatively impact the overall prognosis for these high-risk patients.
• Percutaneous coronary intervention (PCI) is a common procedure for AMI, often involving contrast agents that can trigger CIN.

Purpose of the Study:

• To evaluate the efficacy of spironolactone in preventing CIN in patients with AMI and CKD undergoing PCI.
• To assess the long-term impact of spironolactone on cardiac re-hospitalization and cardiac death in this patient population.

Main Methods:

• Retrospective analysis of 410 patients with AMI and CKD undergoing PCI.
• Patients were divided into standard treatment (n=240) and spironolactone groups (n=170).
• Spironolactone was administered 2 days before and 3 days after PCI; CIN defined by serum creatinine increase within 48-72h.

Main Results:

• CIN incidence was significantly lower in the spironolactone group (11.2%) compared to the standard treatment group (26.7%) (P < .001).
• Long-term spironolactone use (median 42 months) was associated with significantly reduced risks of cardiac re-hospitalization (HR: 0.515) and cardiac death (HR: 0.612).

Conclusions:

• Spironolactone may effectively lower the risk of CIN in patients with AMI and CKD undergoing PCI.
• Long-term administration of spironolactone appears to reduce adverse cardiac events, including re-hospitalization and death, in this vulnerable patient group.